

Development of Selective ROCK Inhibitors for the Treatment of Open-Angle Glaucoma

Pusan National University



OPHTHALMOLOGY	Lead
Product Type	Small molecules
Indication	Open-Angle Glaucoma (OAG)
Target	ROCK
MoA(Mechanism of Action)	ROCK (Rho-associated coiled-coil kinase) inhibitor
Competitiveness	Best-in-class: Overcoming the off-target toxicity limits of FDA-approved drug by securing a ≥ 50 -fold selectivity profile for ROCK over PKA
Development Stage	Lead
Route of Administration	Ocular administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.